See more : Latham Group, Inc. (SWIM) Income Statement Analysis – Financial Results
Complete financial analysis of Precigen, Inc. (PGEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Precigen, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- CK Life Sciences Int’l., (Holdings) Inc. (0775.HK) Income Statement Analysis – Financial Results
- Aurwest Resources Corporation (AURWF) Income Statement Analysis – Financial Results
- Kotobuki Spirits Co., Ltd. (2222.T) Income Statement Analysis – Financial Results
- Blueknight Energy Partners, L.P. (BKEPP) Income Statement Analysis – Financial Results
- Yihai International Holding Ltd. (YNNHF) Income Statement Analysis – Financial Results
Precigen, Inc. (PGEN)
About Precigen, Inc.
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.23M | 26.91M | 103.87M | 103.18M | 90.72M | 160.57M | 230.98M | 190.93M | 173.61M | 71.93M | 23.76M | 13.93M | 8.01M |
| Cost of Revenue | 6.12M | 6.34M | 58.39M | 55.51M | 61.40M | 63.29M | 62.79M | 61.64M | 63.93M | 19.26M | 48.17M | 64.03M | 0.00 |
| Gross Profit | 106.00K | 20.57M | 45.49M | 47.67M | 29.32M | 97.29M | 168.19M | 129.29M | 109.68M | 52.67M | -24.41M | -50.11M | 8.01M |
| Gross Profit Ratio | 1.70% | 76.44% | 43.79% | 46.20% | 32.32% | 60.59% | 72.82% | 67.72% | 63.18% | 73.22% | -102.71% | -359.85% | 100.00% |
| Research & Development | 48.61M | 47.17M | 50.14M | 41.64M | 101.88M | 404.59M | 143.21M | 112.14M | 147.48M | 58.98M | 48.17M | 64.19M | 70.23M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 137.81M | 146.10M | 142.32M | 109.06M | 63.65M | 33.62M | 24.90M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 40.42M | 48.01M | 74.12M | 91.70M | 100.84M | 137.81M | 146.10M | 142.32M | 109.06M | 63.65M | 33.62M | 24.90M | 18.30M |
| Other Expenses | 0.00 | 1.54M | -330.00K | -165.00K | 3.45M | 630.00K | 1.01M | 1.70M | 1.31M | -168.00K | -162.00K | -101.00K | -1.00K |
| Operating Expenses | 84.18M | 95.18M | 124.26M | 133.35M | 202.72M | 542.39M | 289.31M | 254.45M | 256.54M | 122.63M | 81.78M | 89.08M | 90.44M |
| Cost & Expenses | 95.15M | 101.52M | 182.65M | 188.86M | 264.12M | 605.68M | 352.10M | 316.09M | 320.47M | 141.89M | 81.78M | 89.08M | 90.44M |
| Interest Income | 3.24M | 133.00K | 1.62M | 2.45M | 3.87M | 19.08M | 19.49M | 10.19M | 1.88M | 806.00K | 166.00K | 5.00K | 0.00 |
| Interest Expense | 468.00K | 6.77M | 18.89M | 18.40M | 17.67M | 8.53M | 611.00K | 861.00K | 1.24M | 666.00K | 141.00K | 57.00K | 183.00K |
| Depreciation & Amortization | 6.67M | 7.19M | 8.14M | 15.04M | 16.14M | 24.11M | 31.15M | 24.57M | 17.74M | 10.42M | 7.21M | 7.98M | 4.34M |
| EBITDA | -89.23M | -66.00M | -84.07M | -70.41M | -137.46M | -349.06M | -97.94M | -168.72M | -67.99M | -74.64M | -33.56M | -73.83M | -80.76M |
| EBITDA Ratio | -1,433.35% | -267.84% | -74.60% | -81.93% | -185.73% | -272.15% | -49.75% | -70.39% | -87.91% | -103.69% | -247.44% | -485.08% | -974.54% |
| Operating Income | -88.92M | -74.61M | -78.78M | -85.68M | -173.40M | -505.61M | -137.89M | -125.17M | -146.86M | -69.96M | -58.02M | -75.16M | -82.43M |
| Operating Income Ratio | -1,428.48% | -277.25% | -75.84% | -83.04% | -191.14% | -314.88% | -59.70% | -65.56% | -84.60% | -97.26% | -244.20% | -539.73% | -1,028.67% |
| Total Other Income/Expenses | -7.44M | -5.36M | -19.56M | -18.35M | -35.29M | -26.25M | 17.80M | -68.99M | 59.89M | -15.76M | 17.12M | -6.72M | -2.85M |
| Income Before Tax | -96.36M | -79.97M | -96.93M | -103.86M | -208.69M | -536.23M | -129.70M | -194.15M | -86.98M | -85.72M | -40.91M | -81.87M | -85.28M |
| Income Before Tax Ratio | -1,547.98% | -297.17% | -93.31% | -100.66% | -230.03% | -333.95% | -56.15% | -101.69% | -50.10% | -119.17% | -172.17% | -587.96% | -1,064.27% |
| Income Tax Expense | -458.00K | -189.00K | -160.00K | -82.00K | -930.00K | -21.53M | -2.88M | -3.88M | 1.02M | -103.00K | -9.76M | -318.00K | 182.00K |
| Net Income | -95.90M | -79.78M | -96.77M | -103.77M | -207.76M | -509.34M | -117.02M | -186.61M | -84.49M | -81.82M | -38.98M | -81.87M | -85.28M |
| Net Income Ratio | -1,540.63% | -296.47% | -93.16% | -100.58% | -229.00% | -317.20% | -50.66% | -97.74% | -48.67% | -113.75% | -164.06% | -587.96% | -1,064.27% |
| EPS | -0.39 | -0.40 | -0.49 | -0.62 | -1.35 | -3.93 | -0.98 | -1.58 | -0.76 | -0.83 | -0.95 | -14.80 | -15.05 |
| EPS Diluted | -0.39 | -0.40 | -0.49 | -0.62 | -1.35 | -3.93 | -0.98 | -1.58 | -0.76 | -0.83 | -0.95 | -14.80 | -15.05 |
| Weighted Avg Shares Out | 244.54M | 200.36M | 197.76M | 167.07M | 154.14M | 129.52M | 120.00M | 117.98M | 111.07M | 99.17M | 40.95M | 5.53M | 5.66M |
| Weighted Avg Shares Out (Dil) | 244.54M | 200.36M | 197.76M | 167.07M | 154.14M | 129.52M | 120.00M | 117.98M | 111.07M | 99.17M | 40.95M | 5.53M | 5.66M |
Precigen, Inc. (PGEN) Reports Q3 Loss, Lags Revenue Estimates
Precigen Reports Third Quarter 2024 Financial Results and Business Updates
Precigen to Participate in the Stifel 2024 Healthcare Conference
Precigen to Participate in the 2024 Cantor Global Healthcare Conference
3 Penny Stocks To Buy With Just $50
3 Penny Stocks to Buy With $500
Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session
Precigen, Inc. (PGEN) Q2 2024 Earnings Call Transcript
Precigen, Inc. (PGEN) Reports Q2 Loss, Misses Revenue Estimates
Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates
Source: https://incomestatements.info
Category: Stock Reports